Delivery Order SPE2DB24D8003-SPE2DB24FJTPM
Award Date
9/16/24
Potential Completion Date
9/17/24
Potential Value
$7.5K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $5,601.75 contract is for the supply of Dupixent 300 mg/2 ml syringes, with a performance period through August 1, 2024. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has a ceiling value of $29,253.41 and a period of performance through September 19, 2024. Dakota Drug, Inc. is an experienced federal contractor, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $7,274.15 firm fixed-price delivery order is for the pharmaceutical product DUPIXENT 300 MG/2 ML SYRINGE 2ML, with a period of performance through February 1, 2024. Dakota Drug, Inc. holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, as part of the ECAT Generation V Program, which allows the...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $13,666.77, is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. The contract is a firm-fixed-price, unrestricted (no set-aside) contract with a performance period ending on April 29, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a small disadvantaged business located in Anoka, Minnesota. The contract is for the delivery of pharmaceutical products, specifically Dupixent 300 mg/2 ml syringes, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $3,734.50 and a performance period ending on April 28, 2025. Dakota Drug, Inc. also holds a larger Indefinite Delivery Contract (IDC) with...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $6,356.82. The contract is a delivery order with a firm fixed price and an ultimate completion date of March 12, 2025. The contract is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract has a firm fixed price of $3,179.33 and a period of performance through February 26, 2025. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, under the DLA Troop Support Medical's ECAT Generation V Program. This IDC allows...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business. The $15,240.12 contract is for the supply of Dupixent 300 mg/2 ml syringes, with a period of performance through March 19, 2024. Dakota Drug, Inc. has a long history of providing pharmaceutical products and medical supplies to the U.S. Armed Forces through prime contracts and blanket purchase agreements with...
The Defense Logistics Agency (DLA) awarded a $5,339.83 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has an ultimate completion date of July 24, 2024 and is part of the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical equipment, accessories, consumables, and medical simulation equipment. Dakota Drug,...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, involves the delivery of Dupixent 300 mg/2 ml syringes to the Defense Logistics Agency (DLA) Troop Support Medical division. The contract has a firm fixed price of $2,345.09 and a period of performance through November 15, 2023. This award is part of Dakota Drug's larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows the company...